Discovery & Early Development Services
KCAS Bio is poised to perform bioanalytical drug discovery including assessment of a compound’s physiochemical properties, metabolite screening, bioavailability, toxicity and pharmacokinetics. KCAS Bio brings the full power of LBA and LC-MS/MS to your Drug Discovery and early stage research projects.
Rapid, rigorous drug discovery services
KCAS Bio organizes teams around early-stage rapid method development and analysis, as well as regulated preclinical and clinical phases, with support offered through NDA submission. We help with study design and perform the TK assessment once the bioanalytical data are available.
Our people
Tell us how we can help with your project
We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.
Related services
Resources & insights
Blogs
Drug discovery is an essential part of the drug development process. Researchers test candidates to identify those suitable for regulated animal studies and, ultimately, clinical trials. Bioanalytical discovery involves assessing a compound’s physiochemical properties,…
Blogs
Screening experiments have become the backbone of modern drug discovery and biological research, enabling the evaluation of thousands of compounds simultaneously. However, screening success hinges on two critical factors: (1) selecting appropriate cellular models and (2) designing robust experimental frameworks. Poor choices can lead to irreproducible results, failed clinical translation,…
Podcasts
In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their…
Agile, responsive, and easy to work with
We prepare and adapt our services based on a deep understanding of your drug development ambitions and wider business objectives.